PQQ Shows Promise for Reversing Mitochondrial Skin Aging But Needs Rigorous Trials

Mitochondrial dysfunction is increasingly understood as a root driver of visible skin aging — reducing ATP output, amplifying reactive oxygen species (ROS), promoting cellular senescence, degrading extracellular matrix, and impairing barrier repair. Pyrroloquinoline quinone (PQQ), a tricyclic ortho-quinone redox cofactor first identified in bacteria, has attracted growing interest as a mitochondrial rejuvenation agent. This narrative review by Yi (2026), published in Biomolecules, provides a detailed mechanistic and translational appraisal of PQQ's potential in aesthetic dermatology, systematically examining evidence from cell models, animal studies, and the sparse human literature through August 2026.

The most cited mechanistic evidence involves the CREB-PGC-1α pathway. Chowanadisai and colleagues demonstrated that PQQ phosphorylates CREB at Ser133, upregulates PGC-1α promoter activity, and increases expression of nuclear respiratory factors and mitochondrial transcription factor A (TFAM). Silencing either CREB or PGC-1α abolished these effects, confirming pathway specificity. Separately, PQQ was shown to raise cellular NAD+ levels and activate SIRT1-dependent deacetylation of PGC-1α, placing it mechanistically alongside nicotinamide riboside and caloric-restriction mimetics. These findings were established primarily in hepatocyte models, not yet in skin cells at adequate scale.

Skin-specific preclinical evidence is more limited but directionally supportive. In UVA-exposed human dermal fibroblasts, PQQ attenuated senescence- and apoptosis-related changes via a SIRT1/NRF2/HO-1-associated pathway. In normal human epidermal keratinocytes, PQQ disodium suppressed UVB-induced active caspase-1 release — a key NLRP3 inflammasome output — though notably, mitochondrial biogenesis was not detectably increased in the keratinocyte or fibroblast systems tested, highlighting that PQQ's effects are cell-type and context dependent. In Bmi-1-deficient mice, a premature-aging model marked by oxidative stress, oral PQQ reduced cutaneous oxidative stress, DNA damage, senescence markers, and MMP expression — findings directly relevant to photoaged skin.

Human evidence is sparse. A small oral supplementation study in subjects with dry skin reported subjective improvements, and one multi-ingredient topical study incorporated an allyl PQQ derivative — but neither isolates PQQ's contribution or provides controlled aesthetic efficacy data. No peer-reviewed, placebo-controlled randomized clinical trial of PQQ alone for any aesthetic endpoint (wrinkles, pigmentation, firmness, post-procedure recovery) has been published. The review also flags a critical physicochemical challenge: free PQQ is highly hydrophilic and poorly suited to passive stratum corneum penetration, meaning topical delivery requires specialized formulation strategies such as nanoparticles, vesicular carriers, or microneedling-assisted delivery — none of which have been clinically validated for PQQ.

Safety data from human oral supplementation studies at doses of approximately 20 mg/day suggest a favorable short-term profile, but injectable or intradermal use would demand a far higher regulatory threshold, including pharmaceutical-grade purity, sterility, endotoxin control, and local toxicology profiling. The review identifies concentration dependence as a central translational concern: like many quinones, PQQ may shift from cytoprotective to pro-oxidant depending on local reducing equivalents, metal ions, and oxygen tension. The author concludes with a clear roadmap: rigorous formulation science, dose-finding studies, validated skin biomarker protocols, and randomized controlled trials with defined aesthetic endpoints are required before PQQ can be responsibly marketed beyond its current GRAS-adjacent oral supplement status.